1. 1379PDImpact of the EML4-ALK variant on the efficacy of alectinib (ALC) in untreated ALK+ advanced NSCLC (aNSCLC) in the global phase III ALEX study. (23rd October 2018) Authors: Dziadziuszko, R; Mok, T S; Camidge, D R; Shaw, A T; Noe, J; Nowicka, M; Liu, T; Mitry, E; Peters, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1807PSTELLAR: Final results of a phase II trial of TTFields with chemotherapy for first-line treatment of pleural mesothelioma. (23rd October 2018) Authors: Grosso, F; Aerts, J G; Madrzak, J; Dziadziuszko, R; Ramlau, R; Cedres, S; Hiddinga, B; van Meerbeeck, J P; Mencoboni, M; Planchard, D; Chella, A; Crino, L; Krzakowski, M J; Ceresoli, G L Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 65PUpdated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. (24th November 2019) Authors: Rolfo, C; Dziadziuszko, R; Doebele, R C; Demetri, G; Simmons, B; Aziez, A; Huang, X; Osborne, S; Paz-Ares, L Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. (14th April 2018) Authors: Novello, S; Mazières, J; Oh, I -J; de Castro, J; Migliorino, M R; Helland, Å; Dziadziuszko, R; Griesinger, F; Kotb, A; Zeaiter, A; Cardona, A; Balas, B; Johannsdottir, H K; Das-Gupta, A; Wolf, J Journal: Annals of oncology Issue: Volume 29:Number 6(2018) Page Start: 1409 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗